Skip to content
AACR Annual Meeting 2026Developing

adebrelimab

10 reports4 sourcesupdated 19 hours ago

Start here

Report excerpt

In the first clinical study of HRS-4642 combined with adebrelimab in previously treated patients with metastatic KRAS G12D-mutant pancreatic cancer, the chemotherapy-free regimen showed manageable safety and preliminary antitumor activity.

Excerpted from cell.com

Coverage timeline

Follow the coverage to see the different angles.

Sep 16
  1. cell.comPick
    Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer

    In the first clinical study of HRS-4642 combined with adebrelimab in previously treated patients with metastatic KRAS G12D-mutant pancreatic cancer, the chemotherapy-free regimen showed manageable safety and preliminary antitumor activity.

Heat trend for this story

Heat now 17·Peak in the comparable set 29 (Oct 22 20:00)·Change over 24h in the comparable set +67%·Participants now 4

Participants counted4
01234
Heat over time
0102030Oct21Oct22Oct22Oct23

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org